These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20004956)

  • 1. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
    Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
    Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
    Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
    Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Saif MW; Elfiky A; Salem RR
    Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Chura JC; Van Iseghem K; Downs LS; Carson LF; Judson PL
    Gynecol Oncol; 2007 Nov; 107(2):326-30. PubMed ID: 17706754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
    Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
    Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
    Abaid LN; Lopez KL; Micha JP; Rettenmaier MA; Brown JV; Goldstein BH
    Eur J Gynaecol Oncol; 2010; 31(3):308-11. PubMed ID: 21077475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
    J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
    Penson RT; Dizon DS; Cannistra SA; Roche MR; Krasner CN; Berlin ST; Horowitz NS; Disilvestro PA; Matulonis UA; Lee H; King MA; Campos SM
    J Clin Oncol; 2010 Jan; 28(1):154-9. PubMed ID: 19917843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.
    Pietzner K; Richter R; Chekerov R; Erol E; Oskay-Özcelik G; Lichtenegger W; Sehouli J
    Anticancer Res; 2011 Aug; 31(8):2679-82. PubMed ID: 21778323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
    Hurt JD; Richardson DL; Seamon LG; Fowler JF; Copeland LJ; Cohn DE; Eisenhauer E; Salani R; O'Malley DM
    Gynecol Oncol; 2009 Dec; 115(3):396-400. PubMed ID: 19804901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
    Martin JY; Urban RR; Liao JB; Goff BA
    J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical predictors of bevacizumab-associated gastrointestinal perforation.
    Tanyi JL; McCann G; Hagemann AR; Coukos G; Rubin SC; Liao JB; Chu CS
    Gynecol Oncol; 2011 Mar; 120(3):464-9. PubMed ID: 21168199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bevacizumab-associated bowel perforation: a case series and review of the literature.
    Badgwell BD; Camp ER; Feig B; Wolff RA; Eng C; Ellis LM; Cormier JN
    Ann Oncol; 2008 Mar; 19(3):577-82. PubMed ID: 18024857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].
    Takano M; Kikuchi Y; Kato M; Yoshikawa T; Kita T
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1981-4. PubMed ID: 19011357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
    Wright JD; Secord AA; Numnum TM; Rocconi RP; Powell MA; Berchuck A; Alvarez RD; Gibb RK; Trinkaus K; Rader JS; Mutch DG
    Int J Gynecol Cancer; 2008; 18(3):400-6. PubMed ID: 17645510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.